Intravenous immunoglobulin [IVIg] is useful for treating several clinical conditions and is largely considered safe, without major adverse events. Here we report a case of acute ST elevation myocardial infarction associated with high dose IVIg administration in a previously healthy 69-year-old male patient of Guillain Barre syndrome. The case is being reported to emphasize the need for treating physicians to be aware of thrombotic complications associated with IVIg. The thrombotic complications associated with IVIg are reviewed in brief , and the measures to reduce them are discussed.
Introduction
Intravenous immunoglobulin [IVIg] is used for treatment of a variety of autoimmune, rheumatologic, and immunodefi ciency [both primary and secondary] disorders and can be life-saving in several of these conditions. Although it has good safety profile, [1] it can be rarely associated with serious adverse events. Thrombotic complications, both arterial and venous, are uncommon adverse events associated with IVIg use. [2] Here, we report a case of acute ST elevation anterior wall myocardial infarction [MI] associated with high dose [2 g/kg] IVIg administration in a previously healthy 69-year-old male patient of Guillain Barre syndrome [GBS] . The case is being reported to draw the attention of treating physicians to this uncommon, but serious adverse event associated with IVIg administration. We have reviewed the literature on thrombotic complications associated with IVIg in brief and measures to reduce them are discussed.
Case Report
A previously healthy, 69-year-old male manual laborer without addictions was admitted with complaints of progressive weakness of all the 4 limbs for 3 days. The weakness initially started in the lower limbs and then ascended rapidly to involve the upper limbs and neck muscles, forcing him to confi ne himself to bed. There was no history of preceding diarrheal illness, upper respiratory tract infection, or exposure to organophosphate insecticides. 
Discussion
IVIg comprises of gamma globulins derived from purifi ed pooled plasma of thousands of donors, consisting mainly of polyspecifi c IgG. Its immunomodulatory and anti-infl ammatory actions have enabled its effective use in several autoimmune and infl ammatory clinical conditions. Adverse reactions are reported in 24-36% of patients after high dose [2 g/kg] IVIg, [2] most being mild and transient such as headaches, fl ushing, fever, chills, fatigue, nausea, diarrhea, blood pressure changes and tachycardia. More serious adverse effects like acute renal failure, thrombotic events, aseptic meningitis, hematologic complications and anaphylactic reactions are much rarer.
Thrombotic complications reported in association with high dose IVIg include both venous [deep venous thrombosis, pulmonary embolism, hepatic veno-occlusive disease] and arterial events [acute myocardial infarction, ischemic stroke, thrombosis of arteriovenous fi stulae created for hemodialysis, spinal cord ischemia], the latter being 4 times more common than the former. [3] Thrombotic events are reported in most clinical conditions where IVIg has been used, with an estimated incidence of 0.15-1.2% per treatment course. [3] Arterial thromboses are more commonly associated with atherosclerotic risk factors such as advanced age, smoking, obesity, dyslipidemia, diabetes mellitus, hypertension, renal dysfunction, and prior coronary or cerebrovascular disease and occur early (77% within 24 hours) after IVIg administration. Venous thromboses occur later (54% more than 24 hours after IVIg administration) and are associated with risk factors such as obesity and immobility. [3] The risk of thrombosis increases signifi cantly when multiple cardiovascular risk factors co-exist. [4] Autonomic dysfunction [AD] in GBS patients per se has been reported anecdotally to cause MI by catecholamine surge and coronary spasm. [5] In our patient, MI followed few days after the initial AD subsided. Our patient, unlike other reported cases of MI with multiple atherosclerotic risk factors, [6, 7] did not have smoking, obesity, dyslipidemia, diabetes mellitus, hypertension, renal dysfunction and prior coronary or cerebrovascular disease as risk factors. Advanced age was the only risk factor he had. MI occurred during the fi fth day of IVIg infusion, in concert with reported timing of occurrence. [3, 6, 7] The infarction was confi rmed by electrocardiography, echocardiography and elevated troponin T.
Proposed mechanisms for thrombosis include some of the following-platelet activation, increased blood viscosity, contamination of IVIg with activated coagulation factors, induced arterial vasospasm, production of vasoconstrictive cytokines and vasculitis. [8] IVIg products from different manufacturers might differ considerably, and factors such as osmolality, pH and excipient used [sodium or sugar], along with volume load and infusion rates determine the adverse effects. [9] It is thought that salt-based high viscosity products might be responsible for initiation of thrombosis and MI. [9] It is recommended to assess carefully, the overall risk of MI, stroke and venous thromboembolism, along with risk benefi t ratio before IVIg use. [4, 7] Maintenance of hydration, a slower rate of infusion [100 mg/kg/hour], combined with antiplatelet therapy [aspirin-300 mg/day] and anticoagulation [enoxaparin-1 mg/kg/day] have been suggested during IVIg infusion to reduce IVIg-related thrombosis. [9, 10] To conclude, IVIg administration in high doses can be rarely associated with thrombotic complications such as acute MI. Adequate hydration and slower rate of infusion, along with careful patient selection based on the risk-benefi t assessment may reduce this complication.
